Gain Therapeutics Inc

NASDAQ:GANXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.

Contact Information

Headquarters

4800 Hampden Lane, Suite 200BETHESDA, MD, United States 20814

Phone

301-500-1556

Fax

302-655-5049

Executives

Executive Chairman of the Board

Khalid Islam

Interim Chief Executive Officer, Chief Financial Officer, Secretary

Gene Mack

Director

Eric Richman

Independent Director

Dov Goldstein

Independent Director

Hans Hasler